Sociedad Americana de Hirudoterapia

Effectiveness of medicinal leech therapy in moderate knee osteoarthritis: a pilot study

Zaidi SM, Jameel SS, Zaman F, Jilani S, Sultana A, Khan SA (2009) · Hindawi Journal of Evidence-Based Complementary & Alternative Medicine · n=30

RCT evidence detailTrial reference
GRADE Very LowInsufficient evidenceCondition: Knee Osteoarthritis
Sample size of this trial compared with other Knee Osteoarthritis trialsWang H 2018264Lauche R 2025240Lauche R 2014237Farzali S 2025181Cui Y 2024144Andereya S 2008113Andereya S 2008113Sarbaev IS 201996Isik M 201790Zaidi SM 200930
This trial (highlighted) by sample size alongside other indexed Knee Osteoarthritis trials. Larger trials generally carry more statistical weight.

Study Profile

Design
single-center, open-label, randomized pilot trial (Karachi)
Sample size (n)
30
Intervention
Two sessions of 2-4 Hirudinaria granulosa leeches at the symptomatic knee, 14 days apart
Comparator
Diclofenac sodium 50mg twice daily for 4 weeks
Primary endpoint
WOMAC composite at week 4
Primary result
WOMAC composite improvement 56% in leech vs 39% in diclofenac at week 4 (p=0.04)
Effect size (Cohen's d)
0.65
Follow-up duration
8 weeks

Key Findings

  • First Unani medicine RCT context for hirudotherapy
  • Used H. granulosa (Indian/South Asian species)
  • Effect emerged at week 2, peaked at week 4
  • Comparator oral NSAID (diclofenac) more stringent than topical preparations
  • Patient adherence to leech 100% — to NSAID 87%

Limitations

  • Small sample (n=30)
  • Open-label
  • Single center, Unani medicine context
  • Short follow-up (8 weeks)
  • WOMAC not formally validated in Urdu

Clinical Implications

Zaidi 2009 is the first RCT-level evidence from a Unani medicine context. As with Karandikar 2018 (Ayurveda), the use of H. granulosa rather than H. medicinalis limits direct US clinical applicability. The trial primarily supports the species-agnostic effect hypothesis. For US clinicians, this trial is best treated as supporting evidence rather than primary citation.

Related Trials

Este sitio web proporciona información educativa y no constituye consejo médico, diagnóstico ni recomendaciones de tratamiento. La terapia con sanguijuelas medicinales conlleva riesgos clínicamente significativos y debe ser realizada únicamente por profesionales calificados bajo protocolos aprobados institucionalmente. La autorización 510(k) de la FDA para sanguijuelas medicinales se limita a indicaciones específicas; las discusiones sobre uso investigativo y fuera de indicación se señalan correspondientemente. Para orientación médica específica, consulte a un profesional de salud calificado.